When GSK laid out $90 million upfront to acquire rights to Scynexis’ antifungal Brexafemme last spring, the British pharma threw a lifeline to a company whose blockbuster launch ambitions had hit the ...
After charting a similar move in Kenya last year, GSK is pulling the plug on its Nigerian operations. Late last week, GSK said it plans to cease commercialization of its prescription medicines and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results